No evidence of increased incidence of breast cancer with insulin glargine
Publication date: 26 February 2015
Modificationdate: 20 October 2016
Insulin glargine is used in the treatment of diabetes. A new study conducted by RIVM in association with the Leiden Academic Centre for Drug Research found no evidence for increased incidence of breast cancer in mice receiving insulin glargine. The study results are in line with previous studies that found insulin glargine did not increase the risk of breast cancer in patients with diabetes.
In the 1980s and 1990s, another type of insulin, AspB10, was
shown to cause breast cancer in rats, and was thus never used in
humans. While insulin glargine is very similar to AspB10 ,
study showed no association with the development of breast cancer.
The study did not support signals few years ago that insulin
glargine (Lantus®) could increase the risk of breast cancer in
older women with type 2 diabetes.